张 媛,李胜泽.Ki-67、P-糖蛋白预测宫颈癌新辅助化疗敏感性的研究进展[J].肿瘤学杂志,2014,20(12):977-981.
Ki-67、P-糖蛋白预测宫颈癌新辅助化疗敏感性的研究进展
Progress in Predictive Value of Ki-67 and P-glycoprotein for Sensitivity to Neoadjuvant Chemotherapy in Cervical Cancer
投稿时间:2014-10-16  
DOI:10.11735/j.issn.1671-170X.2014.12.B003
中文关键词:  宫颈肿瘤  新辅助化疗  Ki-67  P-糖蛋白
英文关键词:cervical neoplasms  neoadjuvant chemotherapy  Ki-67  P-glycoprotein
基金项目:
作者单位
张 媛 蚌埠医学院第一附属医院 
李胜泽 蚌埠医学院第一附属医院 
摘要点击次数: 2328
全文下载次数: 1024
中文摘要:
      摘 要:宫颈癌是女性最常见的恶性肿瘤,巨块型以及局部晚期宫颈癌疗效一直不甚理想。新辅助化疗是一种针对此类型宫颈癌在术前或放疗前有效的辅助治疗方法。Ki-67可以准确地反映肿瘤细胞的增殖情况,是判断肿瘤生物学行为及预后的标志物之一。P-糖蛋白与肿瘤细胞化疗耐药性密切相关。本文阐述了有关Ki-67、P-糖蛋白作为细胞标志物预测宫颈癌新辅助化疗敏感性的研究进展。
英文摘要:
      Abstract:Cervical cancer is the most common cancer in women. The therapeutic response of blocky tumor and locally advanced cervical cancer is unsatisfied. Neoadjuvant chemotherapy is an important treatment for pre-radical operation and pre-radiotherapy of this type cervical cancer. Ki-67 can reflect the proliferation of tumor cells accurately and as a good marker to estimate the tumor biological behavior and prognosis. P-glycoprotein closely relates to chemotherapeutic resistance of tumor cells. This article reviews the previous studies on Ki-67 and P-glycoprotein as a marker to predict the sensitivity of neoadjuvant chemotherapy in cervical cancer.
在线阅读   查看全文  查看/发表评论  下载PDF阅读器